Gladstone in the News
The Gladstone Institutes is gratified to receive media attention from around the globe. Check out the highlights of recent press coverage of Gladstone scientists and research. For other news, please be sure to follow us on Facebook and Twitter.
Scientists at the Gladstone Institutes have created the first "genomic blueprint" of the human heart, unveiling the exact order and timing of genetic events that must take place for an embryonic heart cell to become a beating, life-sustaining organ.
Gladstone investigators Eric Verdin, MD, and Shomyseh Sanjabi, PhD, are researching why patients living with HIV are aging prematurely.
Scientists led by a team at the Gladstone Institutes are getting closer to understanding how much antiretroviral medication people need to take to protect themselves from being infected with HIV.
Reasearchers from Gladstone Institutes in California have created a blueprint map of how the heart developes in time.
Using stem cell technology, next-generation DNA sequencing and computer tools, researchers at the Gladstone Institutes in California, and other academic centers, have mapped how a heart becomes a heart.
Several large clinical trials have demonstrated that a daily oral dose of one or two antiretroviral drugs used to treat HIV infection can prevent infection in an approach known as pre-exposure prophylaxis, or PrEP.
Truvada, the only medication approved by the U.S. Food and Drug Administration for HIV prevention, is effective in blocking the virus even if people do not adhere to their daily regimen perfectly, a new study indicates.
Scientific breakthroughs, one piled on top of another at breakneck speed over the past few years, have put medical researchers on the cusp of curing almost everyone who suffers from hepatitis C, if not wiping out the disease entirely.
Gladstone's Dr. Warner Greene weighs in on latest outbreak of hantavirus at Yosemite National Park.
The Gladstone Institutes is conducting two other trials of Truvada as PrEP. One of those studies is looking at who takes the pill and when it is taken. The study is enrolling 1,600 people on four continents, including San Francisco, Boston and Chicago in the United States.